Focus on HIV Care

Back to articles

Raltegravir effective against resistant HIV-1 infection

KEY POINT

Forty-eight week data from two ongoing double-blind, placebocontrolled studies show that raltegravir (Isentress—Merck) plus optimized background therapy (OBT) is safe and effective for patients infected with resistant HIV-1 infection, including those with a high HIV-1 RNA level, low CD4 cell count, and a low genotypic or phenotypic sensitivity score.

SOURCES

Steigbigel R et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54. 

Cooper DA et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65. 

Havlir DV. HIV Integrase Inhibitors-out of the pipeline and into the clinic. N Engl J Med. 2008;359:416–8.